Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 454

1.

Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action, and Impaired Postprandial Glucose Control.

Famulla S, Hövelmann U, Fischer A, Coester HV, Hermanski L, Kaltheuner M, Kaltheuner L, Heinemann L, Heise T, Hirsch L.

Diabetes Care. 2016 Jul 13. pii: dc160610. [Epub ahead of print]

PMID:
27411698
2.

If PBMs Guard Access to Drugs, Then Quis Custodiet Ipsos Custodies? (Who Will Guard the Guardians?).

Carter AW, Heinemann L.

J Diabetes Sci Technol. 2016 Jul 4. pii: 1932296816658056. [Epub ahead of print]

PMID:
27381029
3.

Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin.

Heinemann L, Baughman R, Boss A, Hompesch M.

J Diabetes Sci Technol. 2016 Jul 3. pii: 1932296816658055. [Epub ahead of print] Review.

PMID:
27378794
4.

Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report.

Maahs DM, Buckingham BA, Castle JR, Cinar A, Damiano ER, Dassau E, DeVries JH, Doyle FJ 3rd, Griffen SC, Haidar A, Heinemann L, Hovorka R, Jones TW, Kollman C, Kovatchev B, Levy BL, Nimri R, O'Neal DN, Philip M, Renard E, Russell SJ, Weinzimer SA, Zisser H, Lum JW.

Diabetes Care. 2016 Jul;39(7):1175-9. doi: 10.2337/dc15-2716. Review.

PMID:
27330126
5.

Boluses in Insulin Therapy: A Commentary.

Ziegler R, Freckmann G, Heinemann L.

J Diabetes Sci Technol. 2016 Jun 5. pii: 1932296816653142. [Epub ahead of print]

PMID:
27271845
6.

Psychosocial Aspects of Continuous Glucose Monitoring: Connecting to the Patients' Experience.

Kubiak T, Mann CG, Barnard KC, Heinemann L.

J Diabetes Sci Technol. 2016 Jun 28;10(4):859-63. doi: 10.1177/1932296816651450. Print 2016 Jul.

PMID:
27234808
7.

HbA1c and Age in Non-Diabetic Subjects: An Ignored Association?

Roth J, Müller N, Lehmann T, Heinemann L, Wolf G, Müller UA.

Exp Clin Endocrinol Diabetes. 2016 May 24. [Epub ahead of print]

PMID:
27219885
8.

Interferences and Limitations in Blood Glucose Self-Testing: An Overview of the Current Knowledge.

Erbach M, Freckmann G, Hinzmann R, Kulzer B, Ziegler R, Heinemann L, Schnell O.

J Diabetes Sci Technol. 2016 Apr 4. pii: 1932296816641433. [Epub ahead of print] Review.

PMID:
27044519
9.

Quality Control of Insulins and Biosimilar Insulins: What Do We Know?

Carter AW, Heinemann L, Klonoff DC; Fellow AIMBE.

J Diabetes Sci Technol. 2016 Jun 28;10(4):811-5. doi: 10.1177/1932296816638923. Print 2016 Jul. No abstract available.

PMID:
26989067
10.

Comment on "The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System" by Bailey et al.

Freckmann G, Pleus S, Schlüter S, Heinemann L.

Diabetes Technol Ther. 2016 May;18(5):334-5. doi: 10.1089/dia.2016.0008. Epub 2016 Feb 22. No abstract available.

PMID:
26900898
11.

AP@home: The Artificial Pancreas Is Now at Home.

Heinemann L, Benesch C, DeVries JH; AP@home Consortium.

J Diabetes Sci Technol. 2016 Jun 28;10(4):950-8. doi: 10.1177/1932296816632002. Print 2016 Jul. Review.

PMID:
26888971
12.

Insulin Infusion Sets: A Critical Reappraisal.

Heinemann L.

Diabetes Technol Ther. 2016 May;18(5):327-33. doi: 10.1089/dia.2016.0013. Epub 2016 Feb 17.

PMID:
26885764
13.

New Insulins, Biosimilars, and Insulin Therapy.

Danne T, Heinemann L, Bolinder J.

Diabetes Technol Ther. 2016 Feb;18 Suppl 1:S43-55. doi: 10.1089/dia.2016.2505. No abstract available.

PMID:
26836429
14.

Reimbursement for Continuous Glucose Monitoring.

Heinemann L, DeVries JH.

Diabetes Technol Ther. 2016 Feb;18 Suppl 2:S248-52. doi: 10.1089/dia.2015.0296.

15.

Integrated Personalized Diabetes Management (PDM): Design of the ProValue Studies: Prospective, Cluster-Randomized, Controlled, Intervention Trials for Evaluation of the Effectiveness and Benefit of PDM in Patients With Insulin-Treated Type 2 Diabetes.

Kulzer B, Daenschel W, Daenschel I, Siegel EG, Schramm W, Parkin CG, Messinger D, Weissmann J, Djuric Z, Mueller A, Vesper I, Heinemann L.

J Diabetes Sci Technol. 2016 May 3;10(3):772-81. doi: 10.1177/1932296815617487. Print 2016 May.

PMID:
26645793
16.

Toward Development of Psychosocial Measures for Automated Insulin Delivery.

Weissberg-Benchell J, Hood K, Laffel L, Heinemann L, Ball D, Kowalski A, Peters A, Damiano E, Schiller M, Davis A, Beck S, Barnard K.

J Diabetes Sci Technol. 2016 May 3;10(3):799-801. doi: 10.1177/1932296815619637. Print 2016 May.

PMID:
26645792
17.

Options for the Development of Noninvasive Glucose Monitoring: Is Nanotechnology an Option to Break the Boundaries?

Thomas A, Heinemann L, Ramírez A, Zehe A.

J Diabetes Sci Technol. 2016 May 3;10(3):782-9. doi: 10.1177/1932296815616133. Print 2016 May. Review.

PMID:
26581879
18.

Home Use of an Artificial Beta Cell in Type 1 Diabetes.

Thabit H, Tauschmann M, Allen JM, Leelarathna L, Hartnell S, Wilinska ME, Acerini CL, Dellweg S, Benesch C, Heinemann L, Mader JK, Holzer M, Kojzar H, Exall J, Yong J, Pichierri J, Barnard KD, Kollman C, Cheng P, Hindmarsh PC, Campbell FM, Arnolds S, Pieber TR, Evans ML, Dunger DB, Hovorka R; APCam Consortium; AP@home Consortium.

N Engl J Med. 2015 Nov 26;373(22):2129-40. doi: 10.1056/NEJMoa1509351. Epub 2015 Sep 17.

19.

Biosimilar Insulin and Costs: What Can We Expect?

Heinemann L.

J Diabetes Sci Technol. 2015 Sep 8;10(2):457-62. doi: 10.1177/1932296815605337.

PMID:
26350722
20.

Performance Comparison of CGM Systems: MARD Values Are Not Always a Reliable Indicator of CGM System Accuracy.

Kirchsteiger H, Heinemann L, Freckmann G, Lodwig V, Schmelzeisen-Redeker G, Schoemaker M, Del Re L.

J Diabetes Sci Technol. 2015 Sep 1;9(5):1030-40. doi: 10.1177/1932296815586013. Print 2015 Sep.

PMID:
26330485
Items per page

Supplemental Content

Loading ...
Write to the Help Desk